Purpose Monozygotic twins provide an excellent tool to study environmental eVects on human health. Poly(ADPribose) polymerase-1 (PARP-1) is an important enzyme primarily involved in DNA repair and genomic stability and is under clinical investigation as a target for anticancer therapy. As a part of a PARP pharmacogenetics study, elderly male monozygotic twins, one healthy and the other with a Trojani grade 3 sarcoma treated with doxorubicin (DOX: 142.5 mg/m 2 ), were recruited for the study. Methods PARP activity and expression were measured in peripheral blood mononuclear cells (PBMCs) by methods validated to GCLP standard and used as a pharmacodynamic endpoint for clinical trials. Results The mean PARP activity for the patient before treatment was 160 pmol PAR/10 6 cells and was similar to that of his brother (130 pmol PAR/10 6 cells). There was approximately ninefold decrease (P = 0.001) in PARP activity in a second sample from the patient taken 21 days after the Wrst DOX administration (17 pmol PAR/10 6 cells) and a decrease in PARP-1 expression. Investigations into BALB/C mice revealed that DOX treatment (5 mg/kg) resulted in a signiWcant transient decrease in PARP activity after 1 h (63% control, P ¿ 0.05) and 24 h (53% control, P ¿ 0.05) but that PARP activity was restored 1 week after DOX treatment (86% control, P = 0.24). Conclusions We showed here that administration of DOX can have a profound eVect on the measured level of PARP activity and expression in PBMCs from patients and animals. Results obtained in clinical trials where PARP activity is used as a pharmacodynamic marker of PARP inhibition could reXect the eVect of a chemotherapeutic on PBMCs rather than the eVectiveness of a tested PARP inhibitor.
Introduction and aims
Monozygotic twins, due to identical genetic constitution, uterine and early environment, provide an excellent material to study the contribution of genes and the environment on human biochemistry, pharmacology and health. Twin studies can help to identify underlying causes of both physical and mental disorders [1] and response to drugs [2] . Large, nationwide twin studies can help to deWne the contributions of nature and nurture to complex and multifactorial diseases such as cancer [3] . The identiWcation of areas of study likely to be worth investing the substantial resources needed for the larger studies comes from initial interesting sporadic observations. Here, for the Wrst time, we investigated PARP activity and expression in monozygotic twin brothers excluding any potential genetic factors that could aVect levels of measured parameters. As a part of a pharmacogenetics study, the elderly male twins, one with a sarcoma that was treated with doxorubicin (DOX) and the other healthy, were recruited to the study.
Soft tissue sarcomas are rare types of cancer accounting for about 1% of adult malignancies (http://www.macmillan. org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/). Sarcomas are usually treated by a surgical excision either alone or in combination with radiotherapy. There are only three drugs, DOX, dacarbazine and ifosfamide, currently used in treatment that give a relatively good response rate of 20% or more in patients with advanced soft tissue sarcomas [4] . DOX (also called adriamycin) is one of the most widely used anticancer agents and has the broadest spectrum of activity involving DNA intercalation, free-radical formation, covalent DNA binding and inhibition of the topoisomerase II resulting in DNA strand breakage. DOX is a widely prescribed chemotherapeutic used to treat many diVerent types of cancers; however, its use in high doses is limited by the occurrence of severe side eVects such as cardiotoxicity, myelotoxicity and Palmar-plantar erythrodysesthesia [5] .
Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNAbinding enzyme activated by DNA single-strand and double-strand breaks and involved in DNA repair, genomic stability, transcription control, cell death and proliferation. Inhibition, or lack, of PARP-1 results in hyper-sensitivity to DNA methylating agents, topoisomerase I poisons and ionising radiation, all used in the treatment of cancer [6] .
Recent in vivo studies demonstrate that PARP inhibition potentiates the antitumour eVects of DOX in p53-deWcient human breast cancer [7] .
Analysis of the samples received from the twin subjects allowed us to investigate the inter-individual variation in PARP activity in subjects with the same genetic background, and we could also investigate how DOX aVects PARP activity in peripheral blood mononuclear cells (PBMCs). The observed decrease in PARP activity following DOX treatment in the patient was then studied in vivo in mice treated with DOX.
Materials and methods
All chemicals and reagents were of the highest quality and supplied by Sigma (Dorset, UK), unless indicated otherwise. The PARP inhibitor AG014699 was supplied by PWzer GRD. The 10H mouse monoclonal primary antibody was generously supplied by Prof. Alexander Bürkle (University of Konstanz, Germany).
Human subjects
The PARP pharmacogenetics study has been reviewed by the appropriate ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The patient and his healthy twin brother (control subject) were consented to donate blood samples under the regulations of local ethics committee. A volume of 20 ml or less of whole blood was collected from the subjects by venipuncture. Blood from the patient was collected just before the Wrst administration of chemotherapy and 21 days after the Wrst administration, just before second cycle of treatment. This was transferred into EDTA blood tubes (BD Vacutainer, Plymouth, UK). PBMCs were then extracted from blood using Lymphoprep™ Tube (Axis-Shield, Norway) according to manufacturer's instructions. The cell pellet was resuspended in 500 l prechilled freezing medium (RPMI plus 10% foetal bovine serum, FBS), supplemented with 10% DMSO, and 1£ Halt protease inhibitor cocktail (Thermo Fisher ScientiWc, Rockford, IL). Samples were stored immediately at ¡80°C.
Animals
The experiments on animals were conducted in accordance with national law and institutional guidelines for the care and use of animals under a protocol approved by local ethics committee. Male BALB/C mice (8-10 weeks of age, 5 mice/group) were treated as follows: untreated controls and mice treated with 5 mg/kg DOX via intraperitoneal injection (IP) and killed 1 h, 24 h and 6 days after treatment. Blood from the Wve animals was pooled to yield suYcient sample for lymphopreparation and collected into tubes containing an anticoagulant (EDTA) and stored on ice for up to 2 h prior to further processing. Blood was then diluted 1:1 with phosphate buVered saline (PBS) 6 ml was layered over 3 ml of Lymhoprep (Axis-Shield, Norway) and processed according to manufacturer's instruction.
Measurement of PARP activity PARP activity was measured by modiWcation of a previously described method [8] validated to GCLP standard and used as a pharmacodynamic endpoint for clinical trials [9] . BrieXy, maximally stimulated PARP activity was measured in triplicate samples of 10 4 cells permeabilised with icecold digitonin (0.15 mg/ml in water) in a reaction mixture containing 350 mol/l NAD + as substrate in excess and 10 g/ml PARP-activating oligonucleotide (CGGAATT CCG) (Europrim, Invitrogen, UK) that mimics DNA strand breaks, in a reaction buVer of 100 mmol/l Tris-HCl and 120 mmol/l MgCl 2 (pH 7.8) in a Wnal volume of 100 l at 26°C in an oscillating water bath. The use of an oligonucleotide to maximally stimulate PARP minimises variation due to accidental activation of PARP by the unintentional induction of DNA breaks during PBMC harvesting and processing. The reaction was stopped after 6 min. by the addition of excess PARP inhibitor (400 l of 12.5 mol/l AG014699), and the cells were blotted along with a poly(ADP-ribose) standard (0-25 pmol: Biomol, Exeter, UK) onto a nitrocellulose membrane (Hybond-N, Amersham, UK) using a purpose-built 48-well manifold. Following incubation with the primary anti-PAR 10H antibody 1:500 in PBS containing 5% non-fat powdered dried milk and 0.5% Tween 20 (PBS-MT) overnight at 4°C then HRP-conjugated goat anti-mouse secondary antibody (1:1,000 in PBS-MT; Dako, Ely, UK) for 1 h at room temperature, the membrane was exposed for 1 min. to enhanced chemiluminescence (ECL) reaction solution (Amersham, Little Chalford, UK), and chemiluminescence was measured using a Fuji LAS3000 with imaging software (Fuji LAS Image version 1.1, Raytek). Results were expressed in light absorbtion units (LAU) relative to the number of cells loaded and subsequently calculated by reference to the poly(ADPribose) standard curve.
Measurement of PARP-1 expression
BrieXy, the cell pellet was lysed in 100 l of Laemmli buVer [10] with 1£ Halt protease inhibitor cocktail (Thermo Fisher ScientiWc) resuspended on ice for 30 min. sonicated on ice for 10 s (Vibracell Sonicator, Sonics and Materials, Danbury, Conn.) and heated in loading dye containing -mercaptoethanol and bromophenol blue at 95°C for 5 min. Lysates (30 g of protein per lane) were loaded onto Tris-HCl 5-20% polyacrylamide gels (BioRad, Hercules, CA) along with puriWed recombinant PARP-1 immunoblotting standard (Biomol, Exeter, UK), and after electrophoresis at 100 V for 2 h (Criterion electrophoresis apparatus, Bio-Rad), the proteins were transferred for 1 h at 4°C into a nitrocellulose membrane (Hybond-C, Amersham, UK) using a Criterion Blotter (Bio-Rad). After blocking for 1 h in PBS-MT, the membrane was incubated overnight at 4°C with shaking with an anti-PARP-1 C2-10 primary antibody (Trevigen, Gaithersburg, MD) diluted 1:2,000 in PBS-MT, washed 3 times for 15 min. in PBS containing 0.5% Tween 20 (PBS-T) and then incubated with the HRP-linked secondary goat anti-mouse antibody (Dako) diluted 1:1,000 in PBS-MT, washed again for 1 h in PBS-T with changing buVer every 5 min. and then dried. The protein was visualised with ECL plus detection kit (Amersham) using the manufacturer's protocol followed by chemiluminescence detection as described above. We quantiWed the PARP-1 expression by reference to puriWed recombinant PARP-1 protein (Biomol) standard curve (0-40 ng). This assay has also been validated to GCLP standard for evaluation of patient samples (E. Mulligan and T. Zaremba, unpublished data).
Statistical analysis
We analysed each pooled sample in triplicate in three independent experiments (animals) or in duplicate (Western blot) and quadruplicate (PAR assay) in single experiment (humans). We calculated P values for PARP activity comparison by the Student's t test using GraphPad Prism4 software (GraphPad, La Jolla, CA) and by Tukey's test (Minitab, Coventry, UK).
Results

Case presentation
A 67-year-old male patient presented in 2006 with a 7-8 cm left proximal vastus medialis mass in the left thigh mass, which on incision biopsy showed a Trojani grade 3 soft tissue sarcoma of non-speciWc type, and no evidence of metastatic disease. Subsequently, the patient had surgery to remove the tumour and received adjuvant radiotherapy (60 Gy in 30 fractions). In 2007, pulmonary metastases and intra-abdominal lymphadenopathy were detected, and the patient received single agent DOX (142.5 mg/m 2 ). Before the Wrst cycle of chemotherapy, the patient was consented for study. A blood sample was obtained and processed according to local ethics committee. The patient revealed that he had an identical twin brother who would be willing to donate a blood sample for the study as a healthy volunteer. The sample was obtained at the same time as the second sample from patient, which took place 3 weeks after administration of the Wrst dose of DOX.
PARP activity
Measurement of PARP activity in PBMCs from the subjects showed that the mean PARP activity for the patient before the treatment was 160 pmol PAR/10 6 cells and that for the healthy volunteer was 130 pmol PAR/10 6 cells. We observed an approximately ninefold decrease in PARP activity in a second sample from the patient taken 21 days after the Wrst drug administration (17 pmol PAR/10 6 cells) (Fig. 1a, b) .
PARP-1 expression
Measurement of PARP-1 expression in PBMCs from the subjects showed that the mean expression for the patient before the treatment was 0.15 ng PARP/ g total cellular protein while for the healthy volunteer was 0.2 ng PARP/ g total cellular protein. We observed a decrease in PARP-1 expression to below the limit of quantiWcation in the patient sample taken after the Wrst cycle of DOX treatment (Fig. 1c) .
PARP activity in mice treated with DOX
The eVects of DOX treatment (5 mg/kg) on PARP activity in PBMCs from mice 1 h, 24 h and 1 week after drug administration are shown in Fig. 2 . We observed decrease in PARP activity 1 h after drug administration (63% control, range 50-88%; P ¿ 0.05, Tukey's test) and after 24 h (53% control, range 12-78%; P ¿ 0.05, Tukey's test). We observed restoration in PARP activity 1 week after DOX treatment (86% control, range 66-112%; P = 0.24, Tukey's test).
Discussion
In this study, we investigated the inter-individual variation in PARP activity and expression in subjects with the same genetic background i.e. homozygotic twins. We found that in the patient's pre-treatment sample, PARP activity and expression were similar to his identical brother. In both subjects, PARP activity was within the range seen in the general population of healthy volunteers and cancer patients (10-2190 pmol/10 6 cells: TZ unpublished data). We showed that an identical genotype gave very similar phenotype, and this Wnding must be taken into account in an ongoing discussion about the factors determining PARP activity in relation to PARP-1 expression in humans.
We also found that after DOX treatment, the patient had much lower PARP activity and PARP-1 expression. This observation suggested that DOX treatment may reduce both parameters.
To conWrm our Wndings, we also investigated DOX treatment in an animal model: PARP activity was also suppressed in male mice treated with DOX (5 mg/kg) 1 and 24 h after drug administration (P ¿ 0.05). However, the eVect was more modest (approximately twofold) compared to the substantial (ninefold) reduction in the patient.
Our Wnding with a decrease in PARP activity after DOX treatment is somewhat in contrast with previous data showing that cardiotoxicity of DOX is a result of oxidative stress (reactive oxygen species, ROS formation) where oxidative DNA breakage leads to PARP activation [11] . We hypothesise that DOX treatment, due to its selective toxicity to diVerent subtypes of blood cells, altered the proWle of the PBMC (mostly lymphocytes) population and that the observed decrease in PARP activity could be due to selective killing of the population of cells with higher PARP activity by DOX. Ranjit et al. [12] showed that diVerent subtypes of PBMCs had diVerent PARP-1 content with B lymphocytes (18-47% of lymphocytes) having the highest expression level (8.64 Units), compared with T lymphocytes (approx. 70% of lymphocytes, 4.2 Units) and monocytes (3-8% of leucocytes, 2.2 Units). If the reason for high PARP-1 expression in B lymphocytes is associated with its role in DNA rearrangement necessary for the production of antibodies, PARP activity in B cells may also be high. At least two studies showed that chemotherapy causes signiWcant reduction in B lymphocyte count. Mackall et al. [13] demonstrated a rapid and severe decrease in B cell number to almost undetectable level after one cycle of chemotherapy (several diVerent regimes including single-agent cyclophosphamide and cyclophosphamide in combination with DOX and vincristine) and up to sixfold decrease in number of T cells in 10 studied patients. Similarly, Hakim et al. [14] showed up to 96% reduction in B cells and >60% reduction in T cells after treatment with FLAC regime (DOX, 5-Xuorouracil, cyclophosphamide). The full recovery in number of B lymphocytes was not observed until 3 months after the last cycle. These data suggest that chemotherapy leads to the depletion of several subtypes of PBMCs, especially B lymphocytes. The decrease in activity in the sarcoma patient treated with DOX could therefore be due to loss of PBMCs with high PARP-1 expression and PARP activity leaving the patient with those that naturally have less PARP-1 and lower activity. However, a larger study would be needed to conWrm such an implication. The much greater eVect of DOX in the patient than in the mice may reXect the time of sampling. If the high PARP-1-expressing cells are culled in a time-dependent fashion, we may not have sampled the mouse PBMCs at the nadir and may have been only measuring the semi-acute eVects of DOX on PARP activity rather than a combined eVect on activity and selective killing of high PARP-1-expressing cells. Further experiments are clearly warranted to determine the time-dependent eVects of DOX on lymphocyte populations with diVerent PARP-1 expression.
This small study showed a profound decrease in PARP activity measured in PBMCs from a patient who underwent chemotherapy treatment. Our hypothesis that this could be due to a selective depletion of B lymphocytes in blood requires further investigation. This Wnding is very important for current and future clinical studies and trials on PARP inhibitors where PARP activity is used as a pharmacodynamic endpoint; here, we demonstrated that a decrease in PARP activity in such studies could be due to an eVect of the chemotherapeutic, as well as the PARP inhibitor, on PBMCs and lead to a false impression of the eVectiveness of the PARP inhibitor. As a potential solution it would be beneWcial to perform Xow cytometry analysis to test the content of diVerent cell subtypes and subsequently measure PARP activity in those cells. The diVerence in PARP activity before and after drug administration would give a real picture of eVectiveness of tested therapy and also information on its toxicity to particular cell subtypes.
